Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. grew its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.2% in the third quarter, Holdings Channel.com reports. The institutional investor owned 310,116 shares of the company’s stock after buying an additional 20,837 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $5,588,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. New Covenant Trust Company N.A. acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $28,000. EntryPoint Capital LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $30,000. UMB Bank n.a. increased its position in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the last quarter. Claro Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter worth about $52,000. Finally, Beach Investment Counsel Inc. PA acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at about $48,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of recent analyst reports. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday. UBS Group lifted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday. Jefferies Financial Group boosted their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Up 0.1 %

Shares of NYSE:TEVA opened at $18.41 on Thursday. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The firm has a market capitalization of $20.85 billion, a PE ratio of -47.19, a price-to-earnings-growth ratio of 1.32 and a beta of 0.88. The firm’s 50-day moving average is $18.02 and its two-hundred day moving average is $16.72. Teva Pharmaceutical Industries Limited has a 1 year low of $8.07 and a 1 year high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The company had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the sale, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.